

15<sup>th</sup> April 2019

Anjuli Sinniah  
ASX Limited  
Level 40 Central Park  
152 - 158 St Georges Terrace  
PERTH WA 6000

Dear Anjuli,

**Resonance Health Limited (“Company”) – Price Query**

We refer to your letter today in relation to the recent increase in the price of the Company’s securities and the volumes of securities traded.

The Company responds as follows, in accordance with the questions and numbering in your letter:

1. The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.
2. Not applicable.
3. The Company is not aware of the reason for the recent trading in its securities, although the Company notes that on 25-26 March 2019 its CEO and non-executive Director, Mitchell Wells conducted an investor roadshow in Sydney and Melbourne (see ASX announcement on 25 March 2019 – “Investor Presentation”). As previously announced, the Company continues to actively assess opportunities to expand its business through a variety of means including, but not limited to, assessing third-party products and services that fit with the Company’s existing core business and distribution network, increased distribution of Resonance Health products through channel partners, and diversification of in-house R&D. The Company turned profitable and cash flow positive during the June 2018 quarter as reported in the Company’s Appendix 4C and 4D (see ASX 4C announcements for June, September and December 2018, and ASX 4D announcement for Half Year to December 2018). In accordance with the ASX Listing Rules the Company intends to lodge its Appendix 4C with the ASX before 30 April 2019.
4. The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
5. The Company confirms that the responses to the above questions have been authorised and approved by the Board or an officer of the Company with delegated authority from the Board to respond to ASX on disclosure matters.

Yours faithfully,



Agha Shahzad Pervez  
Company Secretary



15 April 2019

Mr Agha Shahzad  
Company Secretary

By email: aghas@resonancehealth.com

Dear Mr Shahzad

### **Resonance Health Limited ('RHT'): Price Query**

We note the change in the price of RHT's securities from a close of \$0.12 to an intraday high of \$0.165 today.

We also note the significant increase in the volume of RHT's securities traded today.

### **Request for Information**

In light of this, ASX asks RHT to respond separately to each of the following questions and requests for information:

1. Is RHT aware of any information concerning it that has not been announced to the market which, if known by some in the market,
2. If the answer to question 1 is "yes".
  - (a) Is RHT relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in RHT's securities would suggest to ASX that such information may have ceased to be confidential and therefore RHT may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that RHT may have for the recent trading in its securities?
4. Please confirm that RHT is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that RHT's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of RHT with delegated authority from the board to respond to ASX on disclosure matters.

### **When and where to send your response**

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **2.30 PM AWST today Monday, 15 April 2019**. If we do not have your response by then, ASX will likely suspend trading in RHT's securities under Listing Rule 17.3. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, RHT's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

---

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market. Your response should be sent to me by e-mail at [ListingsCompliancePerth@asx.com.au](mailto:ListingsCompliancePerth@asx.com.au). It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### **Listing Rules 3.1 and 3.1A**

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A. In responding to this letter, you should have regard to RHT's obligations under Listing Rules 3.1 and 3.1A and also to Guidance *Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B*. It should be noted that RHT's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### **Trading halt**

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in RHT's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

### **Suspension**

If you are unable to respond to this letter by the time specified above ASX will likely suspend trading in RHT's securities under Listing Rule 17.3.

### **Enquiries**

If you have any queries or concerns about any of the above, please contact me immediately.

Regards

---

**Anjuli Sinniah**  
Senior Adviser, Listings Compliance (Melbourne)